X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (129) 129
infectious diseases (93) 93
adult (92) 92
male (89) 89
female (85) 85
hiv infections - drug therapy (74) 74
middle aged (69) 69
index medicus (67) 67
immunology (61) 61
hiv (58) 58
virology (46) 46
drug therapy (44) 44
aids (37) 37
anti-hiv agents - therapeutic use (36) 36
antiretroviral therapy (34) 34
hiv infections - virology (34) 34
treatment outcome (34) 34
human immunodeficiency virus--hiv (33) 33
drug therapy, combination (31) 31
viral load (31) 31
hiv infection (29) 29
aged (25) 25
cd4 lymphocyte count (25) 25
health aspects (25) 25
clinical trials (23) 23
research (23) 23
aids/hiv (22) 22
hiv infections - immunology (22) 22
antiviral agents (21) 21
double-blind method (21) 21
hiv-1 (21) 21
hiv-1 - drug effects (21) 21
risk factors (20) 20
antiretroviral drugs (19) 19
efficacy (19) 19
hiv patients (19) 19
infection (19) 19
infections (19) 19
analysis (18) 18
hiv infections - complications (18) 18
medicine, general & internal (18) 18
protease inhibitors (18) 18
zidovudine (18) 18
active antiretroviral therapy (17) 17
anti-hiv agents - administration & dosage (17) 17
highly active antiretroviral therapy (17) 17
human-immunodeficiency-virus (16) 16
adolescent (15) 15
epidemiology (15) 15
microbiology (15) 15
reverse transcriptase inhibitors - therapeutic use (15) 15
double-blind (14) 14
hiv protease inhibitors - therapeutic use (14) 14
hiv-1 - isolation & purification (14) 14
lamivudine (14) 14
pharmacology & pharmacy (14) 14
rna, viral - blood (14) 14
acquired immune deficiency syndrome--aids (13) 13
care and treatment (13) 13
drug resistance (13) 13
efavirenz (13) 13
patients (13) 13
anti-hiv agents - adverse effects (12) 12
antiretrovirals (12) 12
cohort studies (12) 12
europe (12) 12
genotype (12) 12
hiv-1 - genetics (12) 12
human immunodeficiency virus (12) 12
lamivudine - therapeutic use (12) 12
medical research (12) 12
mortality (12) 12
prospective studies (12) 12
therapy (12) 12
young adult (12) 12
acquired immunodeficiency syndrome - complications (11) 11
anti-retroviral agents - therapeutic use (11) 11
antiretroviral therapy, highly active (11) 11
evaluation (11) 11
hiv-infected patients (11) 11
ritonavir - therapeutic use (11) 11
hiv infections - epidemiology (10) 10
hiv-1 - physiology (10) 10
hiv/aids (10) 10
aids-related opportunistic infections - drug therapy (9) 9
combination therapy (9) 9
hiv 1 (9) 9
hiv infections (9) 9
lymphocytes (9) 9
placebo-controlled trial (9) 9
prevention (9) 9
safety (9) 9
tenofovir (9) 9
virus diseases (9) 9
viruses (9) 9
abridged index medicus (8) 8
drug resistance, viral (8) 8
drug-resistance (8) 8
hepatitis (8) 8
hiv-1-infected patients (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 19, pp. 1807 - 1818
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2012, Volume 12, Issue 1, pp. 27 - 35
Summary Background Elvitegravir is a once daily inhibitor of HIV-1 integrase boosted by ritonavir. We aimed to compare the efficacy and safety of elvitegravir... 
Infectious Disease | INFECTIOUS DISEASES | DARUNAVIR-RITONAVIR | TREATMENT-NAIVE | DOSE-RESPONSE | COMBINATION THERAPY | TMC125 ETRAVIRINE | HIV-1-INFECTED PATIENTS | INFECTION | PLACEBO-CONTROLLED TRIAL | INTEGRASE INHIBITOR | SUBGROUP | Humans | Middle Aged | Male | RNA, Viral - blood | Alanine Transaminase - blood | Diarrhea - chemically induced | Viral Load | Oligopeptides - therapeutic use | Pyrrolidinones - administration & dosage | HIV Infections - immunology | Drug Therapy, Combination - adverse effects | Quinolones - adverse effects | Quinolones - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Female | Raltegravir Potassium | Pyridines - therapeutic use | Anti-Retroviral Agents - therapeutic use | Pyrrolidinones - adverse effects | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | Pyrrolidinones - therapeutic use | Treatment Outcome | CD4 Lymphocyte Count | HIV Protease Inhibitors - therapeutic use | HIV-1 - immunology | Quinolones - administration & dosage | Aspartate Aminotransferases - blood | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Lopinavir - therapeutic use | Antiviral agents | Medical research | Protease inhibitors | Proteases | Medicine, Experimental | HIV patients | HIV (Viruses) | Anti-HIV agents
Journal Article
Journal of the International AIDS Society, ISSN 1758-2652, 11/2014, Volume 17, Issue 4 Suppl 3, pp. 19493 - n/a
ART coverage among HIV‐positive population varies, depending on the countries, between 10% (e.g. Indonesia) and 65% (Botswana). Death rates and new HIV... 
Workers | Human immunodeficiency virus--HIV
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 3, pp. 296 - 304
Journal Article
PLoS Pathogens, ISSN 1553-7366, 07/2015, Volume 11, Issue 7, p. e1005063
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2010, Volume 201, Issue 6, pp. 803 - 813
Background. The MERIT (M̄araviroc versus Ēfavir̄enz īn T̄reatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in... 
HIV/AIDS | Tropisms | RNA | HIV | Stock options | Response rates | Viruses | Infections | Post hoc | HIV 1 | Virology | INFECTIOUS DISEASES | EFFICACY | SAFETY | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | LOPINAVIR-RITONAVIR | THERAPY | VIROLOGICAL FAILURE | RESISTANT HIV-1 | INHIBITOR | CORECEPTOR TROPISM | PLUS | Anti-HIV Agents - pharmacology | Lamivudine - administration & dosage | Cyclohexanes - pharmacology | Humans | Middle Aged | Drug Resistance, Viral | Male | Anti-HIV Agents - standards | Viral Load | Zidovudine - administration & dosage | Young Adult | Cyclohexanes - therapeutic use | Receptors, CCR5 - metabolism | HIV-1 - physiology | Adult | Female | Triazoles - standards | Viral Tropism | Drug Therapy, Combination | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Antiviral Agents - pharmacology | Double-Blind Method | HIV-1 - drug effects | Treatment Outcome | Anti-Retroviral Agents | Benzoxazines - standards | Benzoxazines - therapeutic use | Triazoles - pharmacology | Adolescent | Benzoxazines - pharmacology | Cyclohexanes - standards | HIV Infections - drug therapy | Aged | Drug Combinations | Maraviroc | Patient outcomes | Physiological aspects | Dosage and administration | Genetic aspects | Research | Drug therapy, Combination | Drug therapy | HIV infection | Efavirenz | Chemokines
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 14, pp. 1429 - 1441
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e52845
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2009, Volume 4, Issue 6, pp. e6093 - e6093
The persistence of transcriptionally silent but replication-competent HIV-1 reservoirs in Highly Active Anti-Retroviral Therapy (HAART)-treated infected... 
MULTIDISCIPLINARY SCIENCES | Anti-HIV Agents - pharmacology | HIV-1 - metabolism | NF-KappaB Inhibitor alpha | NF-kappa B - antagonists & inhibitors | Humans | Middle Aged | Enzyme Inhibitors - pharmacology | Nucleosomes - metabolism | Cytoplasm - metabolism | I-kappa B Proteins - metabolism | Virus Latency - drug effects | Drug Synergism | Monocytes - virology | Cell Nucleus - metabolism | CD8-Positive T-Lymphocytes - metabolism | Phorbol Esters - pharmacology | Adult | HIV Infections - drug therapy | HIV-1 - enzymology | Aged | Highly active antiretroviral therapy | Antiviral agents | Control | Physiological aspects | Genetic research | Genetic transcription | T cells | HIV (Viruses) | Health aspects | Therapy | Oxidative stress | Histone deacetylase | Transcription | Laboratories | CD8 antigen | Leukocytes (mononuclear) | Viruses | Lymphocytes T | Infections | Activation | Remodeling | DNA-directed RNA polymerase | Synergism | Recruitment | Long terminal repeat | Cell growth | Transfection | Acquired immune deficiency syndrome--AIDS | Lymphocytes | Human immunodeficiency virus--HIV | Peripheral blood mononuclear cells | Elongation | Deoxyribonucleic acid--DNA | NF-κB protein | Latent infection | Gene expression | Ribonucleic acid--RNA | Patients | Virology | CD4 antigen | Polymerase | Monocytes | Inhibitors | Replication | Combined treatment | RNA polymerase II | Index Medicus | HIV Infections | HIV-1 | Enzyme Inhibitors | Virus Latency | I-kappa B Proteins | Anti-HIV Agents | CD8-Positive T-Lymphocytes | Life Sciences | Microbiology and Parasitology | NF-kappa B | Nucleosomes | Phorbol Esters | Cell Nucleus | Cytoplasm | RNA | Acquired immune deficiency syndrome | Deoxyribonucleic acid | Ribonucleic acid | AIDS | HIV | DNA | Human immunodeficiency virus
Journal Article
Journal Article